NASDAQ
Neuren Pharmaceuticals Limited (NURPF) has a free cash flow growth of -102.27% as of Friday, May 29, 2026. This represents a 126.77% decrease compared to its 12-month average of 382.06%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.